What is the antidote for acetaminophen overdose?
Most sensitive test for organophosphate poisoning is which one?
Which of the following is not an adverse effect of cyclosporine?
Bulls-eye retinopathy is seen in toxicity of:
Pancreatitis is a common complication of which one of the following?
Which of the following treatment options for nicotine dependence is considered the least effective?
A 23-year-old female underwent kidney transplantation and developed acute humoral rejection after 8 days, which was successfully managed with tacrolimus and another drug that suppresses both B and T lymphocytes. What is the drug that targets both B and T lymphocytes by inhibiting de novo synthesis of purines?
All of the following drugs cause hirsutism except:
Which of the following drugs is a corticosteroid and not used for treating glaucoma?
For chemotherapy-induced vomiting, which 5-HT3 antagonist has the maximum potency?
Explanation: ***N-acetylcysteine (NAC)*** - **N-acetylcysteine (NAC)** is the specific antidote for acetaminophen overdose, working by replenishing **glutathione** stores in the liver. - Glutathione is crucial for detoxifying the toxic metabolite of acetaminophen, **N-acetyl-p-benzoquinone imine (NAPQI)**, thus preventing **hepatic damage**. *Heparin* - **Heparin** is an **anticoagulant** used to prevent and treat various thrombotic events by inhibiting coagulation. - It has no role in the treatment or detoxification of acetaminophen overdose. *Morphine* - **Morphine** is an **opioid analgesic** primarily used for pain management, acting on opioid receptors in the central nervous system. - It is not an antidote for any specific overdose and would exacerbate respiratory depression if given in an opioid overdose. *Benzodiazepine* - **Benzodiazepines** are a class of drugs with **sedative, anxiolytic, muscle relaxant, and anticonvulsant** properties, commonly used for anxiety, insomnia, or seizures. - They are not an antidote for acetaminophen overdose and would not counteract its hepatotoxic effects.
Explanation: ***RBC acetylcholinesterase*** - Organophosphates primarily exert their toxic effects by **inhibiting acetylcholinesterase** enzymes, leading to accumulation of acetylcholine. - The **RBC acetylcholinesterase** level directly reflects the extent of this enzymatic inhibition in the body and thus the severity of organophosphate poisoning. *OP level in blood* - Measuring organophosphate levels in the blood can confirm exposure, but it does not directly correlate with the **degree of enzyme inhibition** or clinical toxicity. - The blood OP level decreases rapidly as the substance is metabolized or distributed, making it less sensitive for assessing the clinical impact. *OP level in urine* - Organophosphate metabolites are excreted in the urine, and their detection can indicate exposure, especially if the parent compound is not found in blood. - However, urine levels are primarily useful for **biomonitoring exposure** and do not provide an immediate or sensitive measure of acetylcholinesterase inhibition. *OP level in lavage* - Gastric lavage fluid might contain organophosphates if ingested, making it useful for identifying the poison in cases of recent oral exposure. - This method is more for identifying the presence of a toxin rather than assessing the **physiological impact** or severity of the poisoning.
Explanation: ***Hypoglycemia*** - Cyclosporine is known to cause **hyperglycemia** rather than hypoglycemia, due to its inhibitory effects on insulin secretion and increased insulin resistance. - While it can affect glucose metabolism, causing high blood sugar is the more common and established adverse effect. *Hirsutism* - **Hirsutism**, or excessive hair growth, is a well-known and common adverse effect of cyclosporine, particularly noticeable on the face and body. - This effect is often dose-dependent and can be a significant cosmetic concern for patients. *Nephrotoxicity* - **Nephrotoxicity** is a major and dose-limiting adverse effect of cyclosporine, leading to impaired kidney function. - It can manifest as acute or chronic interstitial nephritis and is a primary reason for careful monitoring of renal parameters. *Hypertension* - **Hypertension** is a frequent adverse effect of cyclosporine, contributing to cardiovascular risk in transplant patients. - The drug's effects on vasoconstriction and fluid retention contribute to increased blood pressure.
Explanation: ***Chloroquine*** - **Bulls-eye maculopathy** is a classic and severe manifestation of retinal toxicity associated with **chloroquine** and **hydroxychloroquine** use. - This pattern involves central macular damage with a surrounding ring of preserved photoreceptors, affecting **visual acuity** and **color vision**. *Quinine* - Quinine toxicity primarily affects the **optic nerve** and **retinal vessels**, leading to **vasoconstriction** and **ischemia**, which can cause **optic neuropathy** and **sudden vision loss**. - It does not typically cause the characteristic bulls-eye maculopathy pattern. *Tobacco* - **Tobacco amblyopia** is a form of **toxic optic neuropathy** associated with chronic tobacco use, particularly smoking or chewing. - It is characterized by **progressive, painless vision loss**, often with **central or centrocecal scotomas**, and typically affects the **optic nerve** rather than the macula in a bulls-eye pattern. *Ethanol* - **Ethanol** (alcohol abuse) can lead to **nutritional optic neuropathy**, especially when combined with poor diet and vitamin deficiencies (e.g., **B vitamins**). - This condition affects the **optic nerve** and causes **gradual vision loss** and **central scotomas**, but not the specific bulls-eye retinopathy seen with chloroquine.
Explanation: ***Didanosine (ddI)*** - **Didanosine (ddI)** is a nucleoside reverse transcriptase inhibitor (NRTI) known for causing dose-dependent **pancreatitis** as a significant adverse effect. - Patients on didanosine require monitoring for symptoms and elevated **amylase/lipase** levels. *Zidovudine* - **Zidovudine** (AZT) is an NRTI primarily associated with **bone marrow suppression** (anemia, neutropenia) and myopathy. - While it can cause lactic acidosis, **pancreatitis** is not its most common or dose-limiting side effect. *Zalcitabine* - **Zalcitabine** (ddC) is an NRTI whose primary dose-limiting toxicity is **peripheral neuropathy**, particularly in the extremities. - **Pancreatitis** is a less common adverse effect compared to didanosine. *Stavudine* - **Stavudine** (d4T) is an NRTI frequently associated with **peripheral neuropathy** and **lipoatrophy** (loss of subcutaneous fat). - Although it can also contribute to lactic acidosis, **pancreatitis** is not its characteristic or most common side effect.
Explanation: **Nicotine gums** - Among nicotine replacement therapies, **nicotine gums** often show **lower real-world effectiveness** due to adherence challenges and technique requirements. - They require a **specific chewing technique** (chew-and-park method) which is frequently done incorrectly, reducing nicotine absorption and efficacy. - **Adherence rates** are typically lower compared to patches due to taste issues, jaw discomfort, and the need for frequent dosing throughout the day. - Real-world quit rates with gum tend to be **lower than patches** despite similar pharmacological potential when used correctly. *Nicotine patches* - **Nicotine patches** provide **steady-state nicotine delivery** over 16-24 hours with once-daily application. - They have **superior adherence** compared to other NRTs due to convenience and ease of use. - Consistently demonstrate **higher real-world quit rates** among NRTs, making them a first-line option. *Varenicline* - **Varenicline** is a **partial agonist at α4β2 nicotinic receptors**, reducing cravings while blocking rewarding effects of smoking. - It is the **most effective pharmacological treatment** for smoking cessation (quit rates 30-35% vs 15-20% for NRTs). - Superior efficacy compared to all NRTs in multiple meta-analyses and clinical trials. *Nicotine tablets* - **Nicotine lozenges/tablets** dissolve slowly in the mouth, providing **rapid nicotine absorption** through oral mucosa. - They offer **better discretion and convenience** than gum without the chewing technique requirement. - **Adherence and efficacy** are generally comparable to or slightly better than nicotine gum in clinical studies.
Explanation: ***Mycophenolate mofetil*** - This drug inhibits **inosine monophosphate dehydrogenase**, an enzyme crucial for the **de novo synthesis of guanine nucleotides** in lymphocytes. - This selective inhibition effectively suppresses the proliferation and function of both **B and T lymphocytes**, making it a cornerstone in preventing transplant rejection. *Methotrexate* - **Methotrexate** is an **antimetabolite** that primarily inhibits **dihydrofolate reductase**, interfering with DNA synthesis and cell proliferation. - While it has immunosuppressive effects, its primary mechanism in inhibiting purine synthesis is not de novo synthesis in the same manner as mycophenolate mofetil. *Prednisone* - **Prednisone** is a **corticosteroid** that exerts its immunosuppressive effects through broad anti-inflammatory actions, genomic and non-genomic effects, affecting the function of various immune cells. - It does not specifically target **de novo purine synthesis** as its primary mechanism of immunosuppression. *Cyclophosphamide* - **Cyclophosphamide** is an **alkylating agent** that cross-links DNA strands, leading to cell cycle arrest and apoptosis, particularly in rapidly dividing cells like lymphocytes. - While it is a potent immunosuppressant affecting both B and T cells, its mechanism does not involve the inhibition of **de novo purine synthesis**.
Explanation: ***Heparin*** - Heparin is an **anticoagulant** medication used to prevent blood clots. - Its primary side effects include **bleeding**, **thrombocytopenia**, and **osteoporosis** with long-term use, but not hirsutism. *Phenytoin* - **Phenytoin** is an anticonvulsant commonly associated with **hirsutism** as a side effect. - It can cause excessive hair growth on the face, trunk, and extremities due to its effects on **hair follicles**. *Minoxidil* - **Minoxidil** is a vasodilator primarily used to treat **androgenetic alopecia** (hair loss), but it can cause **hirsutism** as a side effect, especially when used systemically. - When applied topically for hair regrowth, it can still lead to unwanted hair growth in other areas. *Corticosteroids* - Long-term or high-dose use of **corticosteroids** (e.g., prednisone) can cause a range of side effects, including **hirsutism**. - This is often part of a broader spectrum of **Cushingoid features**, such as moon facies and central obesity.
Explanation: ***Prednisolone*** - **Prednisolone** is a potent **corticosteroid** used to reduce inflammation. - While it has various therapeutic uses, **corticosteroids** can cause or worsen **glaucoma** by increasing intraocular pressure and are therefore generally avoided in its treatment. *Brimonidine* - **Brimonidine** is an **alpha-2 adrenergic agonist** used to treat **glaucoma** by reducing aqueous humor production and increasing uveoscleral outflow. - It is not a corticosteroid and directly targets **intraocular pressure (IOP)** reduction. *Dorzolamide* - **Dorzolamide** is a **carbonic anhydrase inhibitor** that effectively treats **glaucoma** by decreasing aqueous humor secretion. - It works by inhibiting the enzyme **carbonic anhydrase** in the ciliary body, and it is not a corticosteroid. *Timolol* - **Timolol** is a **non-selective beta-blocker** that lowers **intraocular pressure** by reducing the production of aqueous humor. - It is one of the most commonly prescribed drugs for **glaucoma** and is not a corticosteroid.
Explanation: ***Palonosetron*** - Palonosetron is a **second-generation 5-HT3 antagonist** [1], [2] known for its **highest potency** and longer duration of action compared to first-generation agents [2]. - Its high affinity for the **5-HT3 receptor** and extended half-life make it particularly effective for both acute and delayed **chemotherapy-induced nausea and vomiting (CINV)** [3]. *Ondansetron* - Ondansetron is a **first-generation 5-HT3 antagonist** [1], [2] that is widely used, but it has a shorter half-life and lower receptor affinity than palonosetron [2]. - While effective for acute CINV, it is generally considered less potent for **delayed-phase CINV**. *Granisetron* - Granisetron is another **first-generation 5-HT3 antagonist** [1], [2] with a potency and duration of action comparable to ondansetron [3]. - It is effective for **acute CINV**, but its efficacy for delayed CINV is similar to other first-generation agents [2]. *Dolasetron* - Dolasetron is also a **first-generation 5-HT3 antagonist** [1], [2] that is available in intravenous and oral forms. - While effective for acute CINV, it does not demonstrate the same high potency or extended duration of action as palonosetron.
Principles of Clinical Pharmacology
Practice Questions
Therapeutic Drug Monitoring
Practice Questions
Drug Toxicity and Overdose
Practice Questions
Antidotes and Their Applications
Practice Questions
Management of Drug Poisoning
Practice Questions
Drug-Induced Liver Injury
Practice Questions
Drug-Induced Kidney Injury
Practice Questions
Drug-Induced Blood Dyscrasias
Practice Questions
Drug-Induced QT Prolongation
Practice Questions
Pharmacovigilance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free